Skip to main content

Advertisement

SpringerLink
Log in

Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors

  • Urology – Letter to the Editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mir MH, Changal KH, Aziz SA, Bhat GM, Lone AR (2016) Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? Int Urol Nephrol 48(11):1811–1816 (Epub 2016 Jul 23)

    Article  CAS  PubMed  Google Scholar 

  2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590. doi:10.1200/JCO.2008.20.1293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R (2015) Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br J Cancer 113(1):12–19. doi:10.1038/bjc.2015.196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Coelho RC, Reinert T, Campos F, Peixoto FA, de Andrade CA, Castro T, Herchenhorn D (2016) Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. Int Braz J Urol 42(4):694–703. doi:10.1590/S1677-5538.IBJU.2015.0226

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ezz El Din M (2016) Utilization of sunitinib for renal cell cancer: an Egyptian University hospital experience. Asian Pac J Cancer Prev 17(7):3161–3166

  6. Barrios CH, Herchenhorn D, Chacón M, Cabrera-Galeana P, Sajben P, Zhang K (2016) Safety and efficacy of sunitinib in patients from Latin America: subanalysis of an expanded access trial in metastatic renal cell carcinoma. OncoTargets Ther 9:5839–5845 (eCollection 2016)

    Article  Google Scholar 

  7. Escudier B, Porta C, Schmidinger M, Algaba F, Patard JJ, Khoo V, Eisen T, Horwich A, ESMO Guidelines Working Group (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):49–56. doi:10.1093/annonc/mdu259

    Article  Google Scholar 

  8. Kawai Y, Osawa T, Kobayashi K, Inoue R, Yamamoto Y, Matsumoto H, Nagao K, Hara T, Sakano S, Nagamori S, Matsuyama H (2015) Factors prognostic for survival in Japanese patients treated with sunitinib as first-line therapy for metastatic clear cell renal cell cancer. Asian Pac J Cancer Prev 16(14):5687–5690

    Article  CAS  PubMed  Google Scholar 

  9. Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J (2016) Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis. Oncotarget 7(19):27044–27054. doi:10.18632/oncotarget.7395

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

    Jamal Zekri & Saba Imtiaz

  2. Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Saudi Arabia

    Mubarak Al Mansour & Waseem Darwish

Authors
  1. Jamal Zekri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saba Imtiaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mubarak Al Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Waseem Darwish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saba Imtiaz.

Ethics declarations

Conflict of interest

The authors declare they have no conflict of interest.

Research involving human participants and/or animals

The study has been approved by the institutional and/or national research ethics committee and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zekri, J., Imtiaz, S., Al Mansour, M. et al. Sunitinib tolerance and efficacy in patients with metastatic renal cell carcinoma according to ethnic and geographic factors. Int Urol Nephrol 49, 459–460 (2017). https://doi.org/10.1007/s11255-017-1502-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-017-1502-5

Keywords

Search

Navigation